Searchable abstracts of presentations at key conferences in endocrinology

ea0081rc4.5 | Rapid Communications 4: Pituitary and Neuroendocrinology 1 | ECE2022

Validation of the ICD-codes for acromegaly – strategies to reduce false positive cases and improve estimation of the incidence in Sweden

Tsatsaris Erika , Robert Jonas , Berinder Katarina , Bonelli Lorenza , Burman Pia , Dahlqvist Per , Hoybye Charlotte , Ragnarsson Oskar , Vouzouneraki Konstantina , AEkerman Anna-Karin , Ekman Bertil , Eden Engstrom Britt

Purpose: We aimed to validate the diagnosis and estimated national incidence of acromegaly reported in the Swedish National Patient Register (NPR), based on clinically reported International Classification of Diseases (ICD-codes), in comparison with the Swedish Pituitary Register (SPR).Methods: All patients in NPR or SPR between 1991-2018 with the ICD-9 or ICD-10 diagnosis of acromegaly and age >18 years at diagnosis were included. The diagnosis was ...

ea0041gp14 | Adrenal (1) | ECE2016

A Phase 3b, open-label, extension study to evaluate the long-term safety of once-daily, dual-release hydrocortisone (DR-HC) in patients with adrenal insufficiency (AI)

Nilsson Anna , Bergthorsdottir Ragnhildur , Burman Pia , Dahlqvist Per , Ekman Bertil , Eden Engstrom Britt , Ragnarsson Oskar , Skrtic Stanko , Wahlberg Jeanette , Achenbach Heinrich , Uddin Sharif , Marelli Claudio , Johannsson Gudmundur

Introduction: Glucocorticoid replacement for adrenal insufficiency (AI) remains inadequate, resulting in high morbidity, premature mortality and quality-of-life (QoL) impairment. This study investigated the long-term safety of dual-release hydrocortisone (DR-HC) in patients with primary AI.Methods: AI patients who completed a randomized, 3-month crossover study of once-daily DR-HC versus thrice-daily conventional immediate-release hydrocortisone plus a 6...

ea0081p10 | Adrenal and Cardiovascular Endocrinology | ECE2022

Comparison of assays for salivary cortisol and cortisone in the diagnosis of Cushing’s syndrome

Backlund Nils , Brattsand Goran , Lundstedt Staffan , Aardal Elisabeth , Bartuseviciene Inga , Katarina Berinder , Burman Pia , Eden Engstrom Britt , Hoybye Charlotte , Isaksson Anders , Ragnarsson Oskar , Ruetschi Ulrika , Wahlberg Jeanette , Olsson Tommy , Dahlqvist Per

Background & Objective: Late night salivary cortisol (LNSC) and 1 mg overnight dexamethasone suppression test (DST) are two of the three recommended screening tests for Cushing’s syndrome (CS). The classical DST uses serum cortisol, but analysis of salivary cortisol and cortisone has shown high diagnostic accuracy at DST (1). Salivary cortisol can be analysed with immunoassays, which suffer from variable degree of cross reactivity with other steroids, or with LC-MS/MS...

ea0081p429 | Pituitary and Neuroendocrinology | ECE2022

Time from first symptoms to diagnosis in patients with pituitary adenomas

Follin Cecilia , Dahlgren Christina , Alkebro Caroline , Burman Pia , Dahlqvist Per , Hoybye Charlotte , Lindgren Margareta , Ragnarsson Oskar , Wik Helena , Warn Maria , Akerman Anna-Karin , Eden Engstrom Britt , Ekman Bertil , Forsgren Maria

Background: Subtle symptoms such as fatigue, weight gain and depression are commonly present for years in patients with pituitary adenoma (PA) before the diagnosis is made. A delayed diagnosis with risk of increased morbidity and mortality may be due to differences between patient-reported symptoms and symptoms reported in the patient’s medical record.Aim: To estimate diagnostic delay and investigate the concordance between patient-reported symptoms...

ea0056p160 | Steroid metabolism + action | ECE2018

Urinary steroid profile in patients with primary adrenal insufficiency under conventional glucocorticoid replacement: a case control study

Espiard Stephanie , McQueen Johanna , Ragnarsson Oskar , Bergthorsdottir Ragnhildur , Burman Pia , Dahlqvist Per , Ekman Bertil , Eden Engstrom Britt , Nilsson Anna G. , Skrtic Stanko , Wahlberg Jeanette , Sherlock Mark , Stewart Paul M. , Johannsson Gudmundur

Introduction: Primary adrenal insufficiency (PAI) leads to a drastically reduced production of steroids from the adrenal cortex, but a few patients may keep some residual adrenal steroid secretion that may simplify replacement therapy and prevent adrenal crisis. Irrespectively, the conventional glucocorticoid (GC) replacement therapy, using thrice-daily oral hydrocortisone, does not restore the patients’ physiological cortisol profile.Objective: The...

ea0070aep596 | Pituitary and Neuroendocrinology | ECE2020

Efficacy and safety of long-acting pasireotide (LA-PAS) in patients with uncontrolled acromegaly: Results from the prospective cohort of european observational acronis study

Pivonello Rosario , Tabarin Antoine , Colao Annamaria , Kaltsas Gregory , Gonzalez-Molero Inmaculada , Neggers Sebastian , Venegas Moreno Eva , Kocjan Tomaz , Karges Wolfram , Krzyzanowska-Mittermayer Katarzyna , Heck Ansgar , Eden Engstrom Britt , Marques Ruben , O’Brien Eamonn , Manne Shobha , Vincenzi Beatrice , Schöfl Christof

Introduction: Results of the first European real-world evidence from retrospective cohort of ACRONIS study previously confirmed the efficacy and tolerability of LA-PAS in heavily pre-treated, uncontrolled acromegaly patients. Here, we report results of the second interim analysis reflecting the prospective cohort.Methods: Patients who were treated with LA-PAS for ≥6 months were included in this analysis. The primary objective was to document treatm...